Equipotent doses of pegylated epoetin ß (CERA) for the treatment of outcome patients with anemia secondary to chronic kidney disease in clinical practice

• Autores: Vicente Escudero Vilaplana, Sergio Plata Paniagua, Arantza Ais Larisgoitia, Carmen Guadalupe Rodríguez González, José M. Bellón Cano
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 15, Nº. 1, 2013, págs. 55-58
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To analyze the equipotent dose relationship between CERA with the rest of erythropoiesis-stimulating agents (ESA) in the treatment of the anemia secondary to chronic kidney disease (CKD) in clinical practice. Method: Descriptive cross-sectional study performed in the included adult outpatients on treatment with ESA for anemia secondary to CKD. Registered variables were: demographic, date of dispensing, type and dose of ESA, prescriber service, hemoglobin, serum creatinine, uremia, C-reactive protein (CRP), albumin and fibrinogen. We analyzed the differences in mean doses obtained regarding those recommended. Results: 136 patients were included. ESA was prescribed as epoetin a in 14% of patients (monthly mean dose, 15,842 IU [6,891]), epoetin ß in 17.6% (monthly mean dose, 16,454 IU [12,170]), darbepoetin a in 50% (monthly mean dose 109 mcg [91]), CERA in 18.4% (monthly mean dose, 75 mcg [47]). Conclusion: The doses of CERA used in clinical practice were lower than those recommended on label